Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 mg | $1,619 | 1-2 weeks |
Description | Seladelpar sodium salt (MBX-8025) is an orally active and specific PPARδ agonist with an EC50 of 2 nM, demonstrating over 750-fold and 2500-fold selectivity compared to the PPARα and PPARγ receptors, respectively. |
Targets&IC50 | PPARδ:2 nM (EC50) |
In vitro | MBX-8025 is an orally active, potent (EC50 = 2 nM) PPARδ agonist, exhibiting 750-fold and 2500-fold higher specificity compared to PPARα and PPARγ receptors, respectively, and is being developed as a lipid-altering agent [2] [3]. |
In vivo | In a study involving Wt mice on an atherogenic diet, Seladelpar sodium salt administration led to a significant reduction of approximately 18% in body weight (P<0.05), whereas its impact on foz/foz mice under the same diet was minimal. Additionally, this compound significantly lowered serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and exhibited a similar, though not significant, effect in Wt mice. Seladelpar sodium salt was effective in normalizing serum cholesterol levels and reducing triglycerides across both mouse genotypes (P<0.05). It also eliminated hepatocyte ballooning (P<0.05) and halved the nonalcoholic fatty liver disease (NAFLD) activity score by approximately 50%. Moreover, the compound notably diminished sirius red-positive areas in foz/foz mice (P<0.05) [4]. |
Alias | RWJ-800025 sodium salt, MBX-8025 sodium salt |
Molecular Weight | 466.45 |
Formula | C21H22F3NaO5S |
Cas No. | 2751530-13-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (107.19 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.